Other equities research analysts also recently issued research reports about the company. Zacks Investment Research raised Luminex Corp. from a hold rating to a buy rating and set a $24.00 price objective for the company in a report on Tuesday, July 26th. Jefferies Group increased their price target on Luminex Corp. from $21.00 to $23.00 and gave the company a hold rating in a research note on Thursday, July 28th. Finally, JPMorgan Chase & Co. upgraded Luminex Corp. from an underweight rating to a neutral rating and increased their price target for the company from $18.00 to $22.00 in a research note on Thursday, August 18th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $23.00.
Luminex Corp. (NASDAQ:LMNX) traded down 0.45% during midday trading on Wednesday, reaching $22.28. 19,619 shares of the company’s stock were exchanged. The company has a market cap of $970.25 million, a P/E ratio of 23.26 and a beta of 0.42. Luminex Corp. has a 12 month low of $17.29 and a 12 month high of $23.75. The company has a 50 day moving average price of $22.01 and a 200 day moving average price of $20.96.
Luminex Corp. (NASDAQ:LMNX) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.15 by $0.18. The company earned $64.20 million during the quarter, compared to the consensus estimate of $61.20 million. Luminex Corp. had a return on equity of 13.65% and a net margin of 16.60%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. On average, equities analysts anticipate that Luminex Corp. will post $0.63 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Teacher Retirement System of Texas boosted its position in Luminex Corp. by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,429 shares of the company’s stock valued at $110,000 after buying an additional 659 shares during the last quarter. Mason Street Advisors LLC purchased a new position in Luminex Corp. during the second quarter valued at $153,000. Creative Planning boosted its position in Luminex Corp. by 1.6% in the third quarter. Creative Planning now owns 8,923 shares of the company’s stock valued at $203,000 after buying an additional 141 shares during the last quarter. Huntington Asset Advisors Inc. purchased a new position in Luminex Corp. during the first quarter valued at $194,000. Finally, Legal & General Group Plc boosted its position in Luminex Corp. by 30.9% in the second quarter. Legal & General Group Plc now owns 10,357 shares of the company’s stock valued at $207,000 after buying an additional 2,446 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.
Luminex Corp. Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.
Receive News & Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.